We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+7.26%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$263M
AUM Growth
+$1.92M
Cap. Flow
-$11.8M
Cap. Flow %
-4.49%
Top 10 Hldgs %
51.63%
Holding
68
New
8
Increased
22
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$5.37M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.68M
3
AERI
Aerie Pharmaceuticals
AERI
+$3.67M
4
RDUS
Radius Health, Inc.
RDUS
+$3.63M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.63M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$7.83M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$6.37M
3
INCY icon
Incyte
INCY
+$6.36M
4
SHPG
Shire pic
SHPG
+$6.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$5.33M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
2 Miscellaneous 1.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
1
Regeneron Pharmaceuticals
REGN
$83.1B
$23.6M 8.98%
48,130
+3,000
+7% +$1.31M
CELG
2
DELISTED
Celgene Corp
CELG
$23.1M 8.76%
177,522
+3,500
+2% +$429K
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$139B
$17.5M 6.64%
135,522
+13,000
+11% +$1.56M
BIIB icon
4
Biogen
BIIB
$32.7B
$16.6M 6.3%
61,108
-14,300
-19% -$3.78M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$11.8M 4.47%
96,641
-28,000
-22% -$3.26M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12.6B
$10.7M 4.08%
118,166
+40,500
+52% +$3.68M
INCY icon
7
Incyte
INCY
$25.9B
$9.76M 3.71%
77,475
-50,000
-39% -$6.36M
AMGN icon
8
Amgen
AMGN
$236B
$8.63M 3.28%
50,104
-17,000
-25% -$2.77M
GILD icon
9
Gilead Sciences
GILD
$185B
$8.62M 3.28%
121,784
+20,000
+20% +$1.33M
ENTL
10
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$5.66M 2.15%
341,468
– –
VTRS icon
11
Viatris
VTRS
$19.4B
$5.43M 2.06%
+140,000
New +$5.37M
SHPG
12
DELISTED
Shire pic
SHPG
$5.4M 2.05%
32,700
-35,500
-52% -$6.2M
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$5.4M 2.05%
177,643
+7,037
+4% +$204K
RDUS
14
DELISTED
Radius Health, Inc.
RDUS
$5.19M 1.97%
114,799
+95,000
+480% +$3.63M
EXEL icon
15
Exelixis
EXEL
$13.7B
$5.1M 1.94%
207,000
+76,000
+58% +$1.61M
NDRM
16
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$5.01M 1.9%
168,025
+59,777
+55% +$1.55M
AERI
17
DELISTED
Aerie Pharmaceuticals
AERI
$4.93M 1.87%
93,822
+78,822
+525% +$3.67M
TSRO
18
DELISTED
TESARO, Inc.
TSRO
$4.68M 1.78%
33,500
+10,000
+43% +$1.45M
PTLA
19
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$4.27M 1.62%
76,000
+50,000
+192% +$2M
JAZZ icon
20
Jazz Pharmaceuticals
JAZZ
$16.3B
$4.2M 1.6%
27,000
– –
STML
21
DELISTED
Stemline Therapeutics, Inc.
STML
$4.17M 1.58%
453,000
+123,000
+37% +$1.03M
ACAD icon
22
Acadia Pharmaceuticals
ACAD
$5.13B
$3.84M 1.46%
137,773
+88,122
+177% +$2.63M
DERM
23
DELISTED
Dermira, Inc.
DERM
$3.76M 1.43%
129,000
+24,000
+23% +$730K
CALA
24
DELISTED
Calithera Biosciences, Inc
CALA
$3.62M 1.38%
12,200
+7,535
+162% +$2.02M
SGYP
25
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$3.43M 1.3%
772,000
+460,000
+147% +$1.9M
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2017 Portfolio in Review

As of Q2 2017, International Biotechnology Trust held 68 positions worth $263M, up 0.73% from $261M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

International Biotechnology Trust withdrew a net $11.8M in Q2 2017, closing 8 positions and reducing 13 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $5.33M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, International Biotechnology Trust opened a new position in Viatris worth $5.43M.

  • International Biotechnology Trust's largest Q2 2017 buy was Viatris: 140,000 shares worth $5.43M.
  • International Biotechnology Trust added most to BioMarin Pharmaceuticals in Q2 2017, an estimated $3.68M increase.
  • International Biotechnology Trust's biggest Q2 2017 reduction was Illumina, cutting an estimated $7.83M.
  • International Biotechnology Trust fully exited Bristol-Myers Squibb in Q2 2017, selling an estimated $5.33M.
  • International Biotechnology Trust's ten largest holdings make up 52% of its $263M portfolio in Q2 2017.
  • International Biotechnology Trust opened 8 new positions and closed 8 in Q2 2017.
  • International Biotechnology Trust's portfolio value rose 0.73% quarter-over-quarter to $263M.

Based on International Biotechnology Trust's 13F filing for Q2 2017, filed 2 Mar 2018.